Fig. 3From: Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancerOS with advanced HER2-positive breast cancer on immune related protein. Positive or high groups had significantly better OS than negative or low group about CFR (c) (p = 0.034, log-rank). Other immune related protein expression were not related to OS: a CD8, b FOXP3, d PD1, e PD-L1, f CD163, g PTEN, h LAG3Back to article page